Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world.

How we evaluated the potential for an existing AI product to treat a rare disease

How we evaluated the potential for an existing AI product to treat a rare disease

Our client had an existing product in the market for the treatment of an autoimmune condition and wished to explore the opportunities for using this drug to treat another more low-prevalence orphan disease where there is no current targeted treatment available. The client wished to determine the market potential for the existing drug and the challenges they may face.

read more »

  • Posted by Helen Parfitt
  • June 2, 2017
  • News

Therapy Watch expands oncology and IBD portfolios

This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in the US.

This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in the US. CML is a rare cancer affecting the white blood cells and accounts for only 20% of all leukaemias affecting adults. The new CML study will include a panel of Haematologists and Haemato-Oncologists reporting on CML patients every month, including both first-line and later-line patients, resulting in over 2000 patient record forms (PRFs). 

read more »